|Número de publicación||US5206219 A|
|Tipo de publicación||Concesión|
|Número de solicitud||US 07/797,221|
|Fecha de publicación||27 Abr 1993|
|Fecha de presentación||25 Nov 1991|
|Fecha de prioridad||25 Nov 1991|
|Número de publicación||07797221, 797221, US 5206219 A, US 5206219A, US-A-5206219, US5206219 A, US5206219A|
|Inventores||Ashok J. Desai|
|Cesionario original||Applied Analytical Industries, Inc.|
|Exportar cita||BiBTeX, EndNote, RefMan|
|Citas de patentes (11), Otras citas (4), Citada por (209), Clasificaciones (35), Eventos legales (16)|
|Enlaces externos: USPTO, Cesión de USPTO, Espacenet|
This invention relates to new oral dosage unit compositions of proteinaceous medicaments which are pharmaceutically elegant and which deliver the medicament, after oral administration, to the villi of the intestinal tract in the form of a microemulsion formed in situ. This invention also relates to methods of using these compositions.
Biologically active compounds which are peptide or protein in nature have proved to be difficult to administer by the oral route to patients in need of treatment. The active material may be degraded by chemical or enzymatic agents in the gut such as the peptidases, strong acid, oxidizing agents and the like. Other factors may be physical instability, denaturation, surface adsorption, aggregation of proteins or precipitation in the gut.
Workers have sought a solution for this art problem in many ways, such as by means of liposome delivery (U.S. Pat. No. 4,356,167), lipid coating (U.S. Pat. No. 4,849,227, WO87/05505), use of peptidase inhibitors (U.S. Pat. No. 4,579,730), prodrugs, targeted microspheres (WO88/01213), coaccervate systems (U.S. Pat. No. 4,849,405) or, lately, emulsion formulations.
The use of oil/water emulsions for the oral delivery of peptides has received particular attention. Earlier work is summarized by M. Shichiri et al. (Acta diabet. lat. 15, 175 (1978)) and W. A. Ritschel (Meth. Find. Exp. Clin. Pharmacol. 13, 205 (1991)). The art terms and disclosures of the latter publication are incorporated herein by reference.
Y. W. Cho et al (PCT patent application WO 90/03164) discloses the use of oral proteinaceous compositions comprising oil/water emulsions which form chylomicra or deliver chylomicra to absorption sites in the gastrointestinal tracts. Cho discloses on page 9, line 23-29 that the hydrophilic phase (aqueous phase) may contain ethanol. In fact, the preferred embodiments, such as in the examples all contain a substantial quantity of ethanol in the aqueous layer of the emulsion. Also the emulsion is preferably adsorbed on particles before encapsulation (Example 3).
The prior art products have drawbacks in that oil/water emulsions are known in the art to have stability problems. The Cho products, when prepared as described in the PCT publication, have a disagreeable oily appearance which is not pharmaceutically elegant. Ethanol is also a well-known denaturant of many proteinaceous medicaments. The microfluidization process described by Cho also can denature the proteinaceous material due to heat and shear involved in the process.
This invention comprises a dosage unit pharmaceutical composition, adapted for oral administration, containing a liquid polyol solvent-lipid cosolvent medium and dissolved therein a dosage unit amount of a biologically active, proteinaceous medicament along with:
A. agents to form a microemulsion in the gastrointestinal tract at the sites of absorption, and
B. agents which will stabilize and solubilize the contents of the pharmaceutical composition.
The active ingredients of the compositions described here are those accepted for use as medicaments and which have proteinaceous or peptidic chemical structures. Their dosage units are those accepted for medical purposes to be effective and non-toxic. The proteinaceous compound is either a pure protein or peptide or it can exhibit sugar residues in its structure. It may be isolated from natural sources, may be wholly or partially synthetic or may be of biotechnical origin. The number of amino acid units can range from 9 to 1,000 and the molecular weights from 1,000 to 100,000 daltons for certain large molecules.
Exemplary of active proteinaceous ingredients are erythropoietin, insulin, growth hormones, calcitonin, GCSF (growth colony stimulating factor), cyclosporine, vasopressin or its agonists and antagonists, t-PA or vampire bat plasminogen amplifier, urokinase, streptokinase, interferons or interleukins.
The active ingredients, in dosage unit quantities, are incorporated into a medium comprising a pharmaceutically acceptable polyol solvent and a pharmaceutically acceptable lipid solvent.
The polyol co-solvent is one or more of the group of polyhydric alcohols consisting of propylene glycol or a polyethylene glycol. Such polyethylene glycols are the polyalkylene glycol products such as those known in the art as the "PEG" series with chemical structures having 2 or 3 carbon atoms in the alkylene moiety and a mean molecular weight of 200 to 4,000.
The liquid lipid co-solvent is one or more of the group of fats or fat-like substances which act as solvents for ingredients of the composition and are liquid at room temperature. The lipid solvent must, of course, be suitable for human use and must be soluble in or freely miscible with the polyol co-solvent. Especially useful are the liquid saturated or unsaturated fatty acids such as oleic acid, isostearic acid, linoleic acid and linolenic acid.
The ratio of the polyol to lipid co-solvents in the medium is selected from the w/w ranges of 1 to 0.5 up to 1 to 5, preferably of 1 to 1.0 up to 1 to 3 and optimally of 1 to 1.6. Typical percentages in the media are about 15-35% of polyol to 30-60% of lipid.
The pre-emulsion medium is substantially non-aqueous and non-alcoholic. At times a minor quantity of water or buffer solution may conveniently be added to the polyol solvent system to dissolve or stabilize certain active ingredients. The aqueous content of the medium should be about 1-5% w/w. "Substantially" means as little as possible but no more than 5% w/w.
The preferred polyol co-solvent is a mixture of polyethylene glycol-propylene glycol in ratios of from 1-9 to 9-1 w/w, advantageously about 9-1.
This invention is not only intended for administration of proteinaceous materials but many other pharmacologically active agents (e.g. captopril, levodopa, propranolol, erythromycin, carbidopa, cimetidine, ranitidine, etc.) which are susceptible to degradation in the stomach and which lack the ability to be absorbed in the body. These active agents can also be administered in the same manner as described herein if they are indeed soluble in the pre-emulsion media described above.
The other components of the pre-emulsion compositions of this invention are agents which serve different functions: some stabilize the formulation; some stabilize or solubilize the active peptide medicament; others, most importantly, are designed to be part of the fatty globules formed by the ingested clear pre-emulsion medium when it reaches the point of absorption in the gut and forms a microemulsion. The lipid component of the solvent system may serve as solvent as well as a component of such fatty globules. These components are described hereafter and are incorporated into the pre-emulsion compositions as will be apparent to one skilled in the art from the following description and examples.
Phospholipids are one of the integral parts of the fatty globule membrane. It is also believed that these compounds act as precursors for the in vivo synthesis of lecithin at the human intestinal epithelium; lecithin thus forms a part of the membrane of the core of the globules. Chemically, phospholipids are glyceryl triesters in which one of the ester functions is an optionally substituted phosphoric acid.
Different types of phospholipids include diacyl phosphatidyl glycerols, diacyl phosphatidylcholines, diacyl phosphatidic acids, diacyl phosphatidyl ethanolamines. The sources of these types of phospholipids are synthetic or natural. Lecithin obtained from egg yolk or soya is a very suitable phospholipid. Other preferred phospholipids include dimyristoyl phosphatidyl choline, and dimyristoyl phosphatidic acid. The lipid phase capable of forming globules in the gastro-intestinal tract from the microemulsion has these additional ingredients:
Cholesterol or a suitable material that would form a fatty material matrix.
Lecithin or another mentioned phospholipid.
Lipophilic surfactant; e.g. long chain saturated/unsaturated fatty acid, which also could be optionally esterified with glycerol to form a mono-, di- or triglyceride. The ester formed can be glycerol or sorbitol esterified by saturated/unsaturated fatty acids namely oleic acid, linoleic acid, isostearic acid or any other suitable fatty acid.
Broad and preferred percentage ranges in the lipid co-solvent (which are w/v. w/w or even v/v) of the above mentioned ingredients are given below. It is to be noted that using the following optimal percentage ranges for the whole composition one could get the most stable formulation.
______________________________________ Broad Preferred Optimal______________________________________Cholesterol 0.5-25 1-10 4-6Lecithin 0.5-40 1-15 8-12Lipophilic Surfactant 0.5-30 1-12 4-8Lipid 0.5-95 5-75 30-50(Solvent Fatty Acid)______________________________________
The proteinaceous formulations using the optimal percentage ranges are preferred. The assumption using the above ranges is always that the percentage compositions do not exceed 100%.
Another highly desirable ingredient to be dissolved initially in the polyol phase is a high HLB surfactant. The HLB value greater than 15 usually suggests hydrophilic properties of the surfactant. HLB means hydrophilic lipophilic balance. The surfactant used would help to form the micro emulsion and also may help in promoting the formation of a complex between the proteinaceious material and the phospholipid. It is desirable that the surfactant used in the formulation be anionic or nonionic. Usually, there are many surfactants which are classified under the above mentioned categories and are pharmaceutically acceptable, safe and non-toxic. A list of surfactants with high HLB values is given. It is well recognized that these surfactants are esters of long chain fatty acids.
______________________________________Example of High HLB SurfactantsChemical HLB______________________________________Esters of Polyethylene Glycol:Polyethylene Glycol Monostearate 19.1Polyethylene Glycol Alkyl Ethers --Polyethylene Fatty Acid Esters:POE Mono and Di StearatePolyoxyethylated Fatty Acids:POE(40) Lauric Acid 17.9POE(40) Oleic Acid 17.4POE(100) Oleic Acid 18.8POE(50) Stearic Acid 17.9POE(100) Stearic Acid 18.8______________________________________
The hydrophilic surfactant may be present in an amount up to 10% (w/w), preferably from 1-5% and typically 1-4% of the polyol solvent phase.
Another component of the formulation is a protease inhibitor. Either it can be used singly or in combination with one or more other protease inhibitors. The purpose of using the protease inhibitors is to inhibit or prevent the degradation of the proteinaceous material. Proteinaceous materials are digested in the GI tract by the enzymatic actions of trypsin, pepsin, chymotrypsin in the stomach and peptidase and amidase in the intestinal lumen. The enzymes are proteolytic in nature and have strong detergent properties. Thusly, they are very powerful in digesting proteins into amino acids for subsequent anabolism. Amino acids are often termed "building blocks" of the body. Thus, it is highly essential that the proteinaceous material which is being delivered orally be saved from the action of these enzymes. Thus, the proteolytic enzyme inhibitor becomes a vital ingredient in the formulation.
Very commonly used enzyme inhibitors are Aprotinin, and soybean trypsin inhibitor. Aprotinin is commercially available as Trasylol®. Aprotinin is generally considered as safe and non-toxic compared to a wide variety of other enzyme inhibitors. The exact amount of Aprotinin to be used will depend upon the activity and the nature of the proteinaceous material. Generally speaking, 0.1-2% (w/w) of the polyol solvent phase is a range which can be used. Aprotinin can be added to the complex of the protein and the phospholipid or can be directly added to the polyol phase. Other inhibitors and their use in this field are described in U.S. Pat. No. 4,579,730 at column 3, lines 18-40.
An optional ingredient which can be added in the hydrophilic phase is a stabilizer for the formulation. For example, a number of well defined stabilizers for proteinaceious material include hydroxypropyl cellulose, hydroxypropyl methylcellulose, carboxy methylcellulose and methylcellulose. Organic acids and their salts like citric acid may also be utilized for stabilization of the protein. Since the proteinaceous material is added to the polyol, the stabilizer will also be added in the same solvent prior to mixing. The amount of the stabilizer is from 3-5% (w/w) of the polyol solvent phase.
In addition to a surfactant of high HLB value used in the polyol solvent, a low HLB surfactant in the lipid solvent may be used. The surfactants which would serve as a general aid in solubilization are not restricted to any particular HLB values. Useful aids include cholesterol, polysorbates, polyoxyethylene stearate, etc. The exact amount to be used will be determined as simply enough to achieve proper solubilization and obtain a stable formulation. In accordance with this invention, it has been found suitable to use Polysorbate 80 in the lipid solvent.
Other adjuvants for preserving the formulation are common in pharmaceutical formulations. The useful agents are preservatives which could be further classified as antioxidants and antimicrobial agents. Long chain unsaturated fatty acids are particularly susceptible to oxidation. Also, other ingredients present in the lipid solvent are prone to oxidation and there is also a possibility of the oils getting rancid, thus it becomes highly desirable for the presence of anti-oxidants. Since the antioxidants need to be present in the lipid solvent, some oil soluble antioxidants like butylated hydroxyanisole, butylated hydroxytoluene, d-αtocopherol, propyl gallate, etc. are used. Typical antioxidant concentrations can be used which are usually a standard practice. Typically, these can be from 0.1-1.5% (w/w or w/v). If the need arises, higher concentrations can also be used. Hydrophilic antioxidants may also be added to the polyol solvent if necessary. Antimicrobial preservatives are very useful in preventing microbial growth. The most commonly used preservatives are parabens, sodium benzoate, benzylalkonium chloride, etc. The amounts can easily be determined by one skilled in the art.
The two co-solvents, each augmented by appropriate active ingredients, protective agents, stabilizing agents and/or fatty globule-forming agents, are mixed together using any mixing device available. The non-aqueous, non-ethanolic pre-emulsion composition of this invention is formed by mixing a certain ratio of polyol solution with lipid solution. The volume:volume ratio of the supplemented hydrophilic:hydrophobic cosolvents is in the range from 0.05 to 0.95, the preferred ratio being 0.3-0.7. A certain ratio can be selected based on the characteristics and the appearance chosen for the pre-emulsion solution. The resulting pre-emulsion composition is a clear liquid which may range from free-flowing to slightly viscous in nature. While the composition itself may be taken by mouth in dosage units, it is more palatable and efficacious to put a dosage unit of peptide in amounts known to art in a plain or enteric capsule which is administered orally from 2-5 times daily to a human or animal subject in need thereof.
The clear pre-emulsion solution, when taken orally, comes in contact with the digestive juices in the gastro-intestinal tract, to form an in-situ micro-emulsion. This emulsion is formed at the villi and the microvilli which are the sites of absorption. This is the unique feature of the invention. The particle size of the emulsion droplets as seen microscopically is between 5-50 microns in diameter.
The pre-emulsion solution is encapsulated into a hard/soft gelatin capsule and the capsule is optionally coated with a pH resistant film which dissolves at a pH greater than 5.5. The gelatin capsule is most effective coated with enteric coating materials which are different polymers. It is observed that an effective enteric coating is obtained using an undercoat. The undercoating polymer can be hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxypropyl ethylcellulose, polyvinylpyridone, etc. According to one variation of the invention, the pre-emulsion solution may be coated onto an adsorbent solid and the subsequent granules formed, such as by using rotary fluid bed techniques, and packed into a capsule. A variety of adsorbent materials like colloidal silicon dioxide, microcrystalline cellulose, lactose, alginic acid, etc. can be used. The capsule should be enteric coated so as to be protected in the stomach. Alternatively, the granules are enteric coated and packed into a capsule or compressed into a tablet. Thus, formulations which are obtained in accordance with the invention can be made in a wide variety of different ways, for example as a pre-emulsion solution into a soft gelatin/hard gelatin capsule, or granules formed by absorbing the solution onto a solid and packing the granules into a capsule which then is enteric coated, or enteric coating the granules obtained by the above process and packing into a hard gelatin capsule. The dosage unit prepared thus is administered orally 2-5 times daily to a human or animal patient in need thereof.
When the pre-emulsion solution is taken orally and is diluted with the intestinal fluids, an in-situ emulsion is formed at the villae and microvillae in the intestinal lumen of the GI tract. This in-situ emulsion has particle size in the range of 5-50 u. The in-situ emulsification process occurs in the small intestine namely the duodenum.
The pre-emulsion solution is encapsulated into a hard/soft gelatin capsule and the capsule is coated with a pH resistant film which dissolves at a pH greater than 5.5. Therefore, the passage of the capsule through the stomach is intact. The capsule opens after entry into the duodenum and an in-situ emulsion is formed to facilitate the absorption of the medicament as described in the prior art cited hereinabove.
Following are specific embodiments to teach the practice of the disclosed invention but not to limit its scope.
For this specific example, insulin as a biologically active proteinaceous material is used to obtain oral absorption from the delivery system. There is no heat involved which might denature the protein. There is also complete absence of alcohol which has been shown to denature peptides/proteins. The high HLB surfactant Myrj-52® is slowly dispersed into the mixture of polyethylene glycol 400 and propylene glycol. Once it dissolves, hydroxypropyl cellulose as a stabilizer is also added which is dispersed slowly into the above mixture. A separate solution of the proteinaceous material along with the phospholipid and the protease inhibitor is made in a portion of the above solvent mixture. The solution can then be added to the PEG/PG mixture at room temperature. The amount of any water is limited to 5% of the polyol solvent. When the water solution is used, citrate buffer is used to maintain the pH at a point where the protein is most stable. In this particular example, if insulin is used, it is suggested that the pH be maintained with a citrate buffer at or around 2.5. Separately, the ingredients of the lipid solvent are mixed together. Under gentle and constant stirring, the polyol solution is dispersed with the lipid solution.
In particular, insulin is delivered orally by the way of this invention. Insulin is a polypeptide consisting of 65 amino acids with an approximate molecular weight of 6,000 and is very widely used all over the world for the treatment and control of diabetes.
______________________________________ % in the % in the Respective mg/ FinalChemicals Solvent Capsule Gm/Batch Formula______________________________________Insulin 140 IU* 118,860 IUDimyristyl 0.027 0.047 0.04 0.0078phosphatidylcholineAprotinin** 1.94 3.39 2.88 0.57Hydroxypropyl 2.14 3.76 3.18 0.64cellulose-LFPoly-oxy 40 2.14 3.76 3.18 0.64stearatePolyethylene 79.90 139.8 118.55 23.73glycol 400Propylene glycol 8.90 15.57 13.20 2.64Water/citrate 5.0 8.75 7.42 1.48buffer(pH adjustment)Cholesterol 7.64 31.2 26.46 5.30Tween 80 4.30 17.56 14.89 2.98Egg yolk lecithin 15.45 63.1 53.51 10.71Glyceryl mono 6.83 27.9 23.66 4.74oleated-α tocopherol 4.80 19.6 16.62 3.33Oleic acid 61.0 249.1 211.24 42.29______________________________________ Activity: *Insulin: 26 IU = 1.0 mg **Aprotinin: 7500 KIU = 1.0 mg
The high HLB surfactant (Poly-oxy-40 stearate) is slowly dispersed into a mixture of polyethylene glycol and propylene glycol. Once it is dissolved, small amounts of hydroxypropyl cellulose are then added and dispersed into the same mixture. Insulin is dissolved in water and citric acid is dissolved in water for maintaining the pH at 2.5. The water solution is added to the polyethylene glycol mixture. In a separate beaker dissolve all the ingredients of the oil phase in oleic acid. Cholesterol is added slowly to achieve faster dissolution. Once both the phases are ready, the polyol solution is added slowly to lipid phase while mixing at low speed. The beaker should be preferably ice jacketed, since heat may be produced. Once the addition is achieved, a transparent yellowish brown solution is obtained.
The pre-emulsion solution is filled in a size 0 hard gelatin capsule and the capsule is sealed with a band of gelatin solution. The banding helps to coat the capsule uniformly. The capsule is then coated with a 10% hydroxypropyl methylcellulose solution as an undercoat. The amount of coat required is sufficient just enough to cover the capsule uniformly with a thin layer of the polymer coat. Usually, 3.5-4.5% weight gain of the capsule is a good indication of the amount required as an undercoat. Once the capsule is coated with an undercoat, enteric coating is applied. For enteric coating purposes, different polymers like hydroxypropyl methyl cellulose, hydroxypropyl methyl cellulose pthalate, cellulose acetate pthalate, etc. are used. Anionic copolymers which are based on methacrylic acid and methyl methycrate, commercially available as Eudragit®, are also very suitable polymers for enteric coating purposes. The polymer is dissolved in organic solvents such as ethyl alcohol, methyl alcohol, acetone, isopropyl alcohol. A combination of two solvents can also be used. The amount of enteric coating solution required is 5-6% weight gain of the capsules from the original weight of the capsules before applying enteric coat. A typical enteric coating solution is made as follows:
______________________________________Methacrylic acid and methyl 10% w/wmethycrate copolymer (polymer)Diethyl butyl pthalate (plasticizer) 2% w/wAcetone 22% w/wIsopropanol 66% w/w______________________________________
Mix acetone and isopropanol. Add the polymer slowly with constant mixing. Once the polymer is dissolved, add the plasticizer slowly and let it dissolve.
For a size 0 capsule the above mentioned enteric coating solution can be sprayed using fluidizing bed techniques. The fluid bed sprayer/dryer is operated with the following parameters:
______________________________________Flow Rate: 1.5 mL/minuteInlet Air Temp: 25° C.Outlet Air Temp: 25° C.Air Flap: 35Atomizer: 2.0 bar______________________________________
A batch size of about 500-525 capsules is optimum for effective uniform coating. A size 0 capsule after the enteric coating will typically have the following composition:
______________________________________Pre-emulsion Solution: 0.589 gUndercoat Polymer: 0.027 gEnteric Coat Polymer: 0.032 g 0.648 g______________________________________
For the example listed below, erythropoietin is used as a proteinaceous material. Erythropoietin is a 165 amino acid glycoprotein of approximately 34,000 daltons. It is an endogenous protein which is involved in the production of red blood cells. It is indicated for the treatment of anemia associated with chronic renal failure, in AIDS patients and also to maintain or elevate the red blood cell level in the human body.
The procedure for making the formulation is same as listed previously in Example 1 except for pH adjustment. For erythropoietin, pH can be adjusted to 7-7.5 with a phosphate buffer. The amount of aqueous buffer solution would still be 5% of the hydrophilic phase. At a pH of 7.0-7.5, erythropoietin has its maximum stability. It is known that in formulating proteins the pH of the formulation should be distant from the isoelectric point of the protein which would not precipitate the protein from the solution.
______________________________________ % in the % in the Respective mg/ FinalChemicals Solvent Capsule Gm/Batch Formula______________________________________Erythropoietin 14,000 5,936,000 IU* IUDimyristyl 0.027 0.047 0.020 0.008phosphatidylcholineAprotinin** 1.94 3.42 1.45 0.58Hydroxypropyl 2.14 3.78 1.60 0.64cellulose-LFPoly-oxy 40 2.14 3.78 1.60 0.64stearatePolyethylene 79.90 141.1 59.83 23.95glycol 400Propylene glycol 8.90 15.72 6.66 2.67Phosphate buffer 5.0 8.83 3.74 1.5Cholesterol 7.64 31.49 13.35 5.35Egg yolk lecithin 15.45 63.68 27.0 10.81d-α tocopherol 4.80 19.78 8.39 3.36Oleic acid 61.0 251.42 106.60 42.69Glyceryl mono 6.83 28.15 11.94 4.78oleateTween 80 4.30 17.72 7.51 3.01______________________________________ Activity: *Erythropoietin: 1000 IU = 8 ug **Aprotinin: 7500 KIU = 1.0 mg
The high HLB surfactant (Poly-oxy-40 stearate) is slowly dispersed into a mixture of polyethylene glycol and propylene glycol. Once it is dissolved, small amounts of hydroxypropyl cellulose are then added and dispersed into the same mixture. Erythropoietin is dissolved in the phosphate buffer/water/saline, along with Aprotinin and dimyristyl phosphatidyl choline. The aqueous solution is then added to the polyethylene glycol mixture at room temperature. The pH of the solution should be adjusted at 7.5 for maximum stability. In a separate beaker dissolve all the lipid-liking ingredients in oleic acid. Cholesterol is added slowly to achieve faster dissolution. Once both the phases are ready, the lipid solution is added slowly to polyol solution while mixing at low speed. The beaker should be preferably ice jacketed, since mixing produces heat. Once the mixing is achieved, a transparent yellowish brown pre-emulsion solution is obtained. The solution can be encapsulated into a capsule and coated according to Example 1.
Alternatively, bile salts or absorption enhancers are also used to enhance the absorption of orally administered proteins and peptides. Ingredients like sodium cholate, sodium deoxycholate, sodium taurocholate, sodium glycocholate are used to enhance the absorption. It is known to the art that some of the acids and their alkali salts are unsuitable for use in orally administered dosage forms due to the damage caused to the cells of the intestinal wall. Generally, the amounts of the bile acid/bile salts used are in the range of 1-20 mg/mL and 8-16 mg/mL often being the preferred concentration. The proteinaceous material in the following embodiment is human growth hormone which has an approximate molecular weight of 22,000 daltons. As a phospholipid, dimyristyl phosphatidic acid or its sodium salt can be used in this particular example. The high HLB surafactant used is Brij 35®. For the lipid solvent mixture, isostearic acid can be added instead of oleic acid. The lipophilic surfactant used in this example is sorbitan monooleate.
______________________________________ % in the % in the Respective mg/ FinalChemicals Solvent Capsule Gm/Batch Formula______________________________________Human Growth 28 IU* 11,872 IU 1.83HormoneDimyristyl 0.027 0.047 0.02 0.008phosphatidic acidAprotinin** 1.95 3.38 1.43 0.57Sodium Cholate 2.0 3.47 1.47 0.59Poly-oxy-23 2.14 3.71 1.57 0.63lauryl etherPolyethylene 79.0 138.60 58.77 23.53glycol 400Propylene glycol 7.9 13.70 5.81 2.33Water/pH 5.0 8.67 3.68 1.47adjusterCholesterol 7.64 30.92 13.11 5.25Egg yolk lecithin 15.45 62.53 26.51 10.61d-α tocopherol 4.8 19.43 8.24 3.30Isostearic Acid 61.0 246.90 104.68 41.92Sorbitan 6.83 27.64 11.72 4.69monooleateTween 80R 4.30 17.40 7.38 2.95______________________________________ Activity: *Human Growth Hormone: 2.6 IU = 1.0 mg **Aprotinin: 7500 KIU = 1.0 mg
Polyoxy-23 lauryl ether (commercially available as Brij® 35) is dispersed in the solvent mixture of polyethylene glycol 400 and propylene glycol. Sodium cholate is also separately dispersed in the mixture. A water solution containing recombinant human growth hormone, phospholipid and Aprotinin is then added to the above solvent mixture and the pH is adjusted to 7.5-7.8 with the help of phosphate buffer. The lipid solution is made separately in another beaker. To the oil solution, the polyol solution is added dropwise while mixing continuously. While mixing, it is suggested that the beaker be ice jacketed to prevent the denaturation of the protein in the formulation. A clear transparent liquid, which is called the pre-emulsion solution, is obtained after approximately 5 minutes of mixing at low speed. An in-situ emulsion can be made by mixing any ratio of the pre-emulsion solution with the simulated intestinal fluid.
Phospholipids are either used singularly or in combination with each other. For this particular example, human or salmon calcitonin is administered orally as a phospholipid complex in the polyol solvent.
When administering calcitonin, it is important that the pH be maintained at 2.0 or 2.5 with the help of a buffer. Calcitonin has maximum stability at pH 2.0.
______________________________________ % in the % in the Respective FinalChemicals Solvent mg/Capsule Gm/Batch Formula______________________________________Salmon Calcitonin 500 IU 212,000 IUDimyristyl 0.027 0.048 0.02 0.008phosphatidic acidPhosphatidyl 0.027 0.048 0.02 0.008cholineHydroxypropyl 2.14 3.78 1.60 0.64cellulose-LFPoly-oxy-40 2.14 3.78 1.60 0.64stearatePolyethylene 79.8 140.97 59.77 23.93glycol 400Propylene glycol 8.8 15.55 6.59 2.64Citrate buffer/ 5.0 8.83 3.74 1.50pH adjusterAprotinin 1.95 3.44 1.46 0.58Cholesterol 7.64 31.49 13.35 5.35Egg yolk lecithin 15.45 63.69 27.0 10.81d-α tocopherol 4.8 19.79 8.39 3.36Isostearic acid 61.0 251.45 106.61 42.69Glyceryl 6.83 28.15 11.94 4.78monooleateTween 80R 4.30 17.72 7.51 3.01______________________________________
The high HLB surfactant (Poly-oxy-40 stearate) is slowly dispersed into a mixture of polyethylene glycol and propylene glycol. Hydroxypropyl cellulose is also added in small amounts into the same solvent mixture. Salmon calcitonin can be dissolved in citrate buffer along with the phospholipids and Aprotinin or citric acid can be added in the water directly. The water solution is added to the solvent mixture with constant mixing. The pH of the polyol solution should be adjusted at 2.5 for maximum stability. Oil phase is made separately in another beaker. To the oil solution, the polyol solution is added slowly with constant homogenization. A clear transparent pre-emulsion composition is obtained. This solution can be filled into a capsule and coated with a suitable polymer according to Example 1.
Objective: Record the percent transmittance of the pre-emulsion medium (from Example 1) in various ratios diluted with simulated intestinal fluid U.S.P.
Instrument: Beckman DU®-37 spectrophotometer, 1 cm cell, Vanderkamp® 600 six spindle dissolution tester.
Procedure: Pour 500 ml of simulated intestinal fluid into the dissolution vessel, set the paddle speed to 200 RPM. Let the fluid warm up to 37° C., then add 5 ml of pre-emulsion medium to the SIF. This is 1:100 ratio of dilution. Make different ratios of dilution of the pre-emulsion with the intestinal fluid. Pour 3-5 ml of sample from the dissolution vessel at 5.0 minute intervals for up to 60.0 minutes. The zero time reading is the percent transmittance of pre-emulsion medium before any addition of the simulated intestinal fluid.
______________________________________ % Transmittance at 800 nmTime in Minutes 1:50 1:100 1:200 1:400______________________________________ 0 92.1 78.6 91.3 92.1 5 0.6 5.4 30.4 56.310 0.6 5.7 29.0 59.315 0.54 5.7 29.8 57.620 0.54 5.7 28.8 57.625 0.47 6.4 32.1 59.130 0.47 6.6 31.8 57.935 0.40 6.1 31.7 56.640 0.40 6.7 32.9 60.845 0.40 6.3 34.6 59.750 0.40 6.0 33.4 59.955 0.40 6.1 34.0 53.660 0.34 6.0 33.0 57.6______________________________________
The data show that the pre-emulsion solution is a transparent solution before the dilution with the intestinal fluid. At 800 nm the light transmitted is approximately 90%. Once the pre-emulsion solution is diluted with the intestinal fluid, an in-situ emulsion is formed and the percent light transmitted drops remarkably. As seen from the data, when the emulsion is more diluted, more light passes through it compared to when it is only diluted 50 times. When it is a concentrated emulsion it is opaque, and it gets more transparent and more light passes through it as the dilution increases. Microscopic studies have shown that a water in oil in water microemulsion is present after dilution with SIF.
|Patente citada||Fecha de presentación||Fecha de publicación||Solicitante||Título|
|US4356167 *||22 Jun 1981||26 Oct 1982||Sandoz, Inc.||Liposome drug delivery systems|
|US4579730 *||9 May 1984||1 Abr 1986||Hadassah Medical Organization||Pharmaceutical compositions containing insulin|
|US4849227 *||3 Mar 1987||18 Jul 1989||Eurasiam Laboratories, Inc.||Pharmaceutical compositions|
|US4880835 *||3 Nov 1988||14 Nov 1989||Formulations Development Labs, Inc.||Oral liquid pharmaceutical compositions of sulindac|
|US4910021 *||25 Nov 1986||20 Mar 1990||R. P. Scherer Corporation||Targeted enternal delivery system|
|EP0152345A2 *||5 Feb 1985||21 Ago 1985||INTERFERON SCIENCES, INC a Delaware Corporation||Interferon administration vehicles|
|WO1987005505A1 *||12 Mar 1987||24 Sep 1987||Eurosium Lab||Pharmaceutical compositions|
|WO1988001213A1 *||14 Ago 1987||25 Feb 1988||Clinical Technologies Ass||Delivery systems for pharmacological agents|
|WO1990001329A1 *||26 Jul 1989||22 Feb 1990||Kanji Takada||Enteric formulations of physiologically active peptides and proteins|
|WO1990003164A2 *||29 Sep 1989||5 Abr 1990||Patralan Ltd||Pharmaceutical formulations|
|WO1991014454A1 *||2 Abr 1991||3 Oct 1991||Skua Investments Ltd||Pharmaceutical formulations|
|1||*||Ritschel Meth Find Exp Clin. Pharmacol. 13(3): 205 220 (1991).|
|2||Ritschel Meth Find Exp Clin. Pharmacol. 13(3): 205-220 (1991).|
|3||*||Shichiri et al. Acta Diabet. Lat. 15: 175 183 (1978).|
|4||Shichiri et al. Acta Diabet. Lat. 15: 175-183 (1978).|
|Patente citante||Fecha de presentación||Fecha de publicación||Solicitante||Título|
|US5290569 *||8 Jun 1992||1 Mar 1994||Shionogi & Co., Ltd.||Coated composition and its preparation process|
|US5424265 *||15 Jun 1993||13 Jun 1995||Safetec Of America||Capsule for absorbing liquid waste in a suction canister|
|US5443842 *||30 Mar 1994||22 Ago 1995||Inverni Della Beffa Farmaceutici S.R.L.||Oral formulations of ubidecarenone in form of capsules|
|US5444041 *||20 May 1992||22 Ago 1995||Ibah, Inc.||Convertible microemulsion formulations|
|US5449720 *||24 May 1993||12 Sep 1995||Biotech Australia Pty Limited||Amplification of the VB12 uptake system using polymers|
|US5514670 *||13 Ago 1993||7 May 1996||Pharmos Corporation||Submicron emulsions for delivery of peptides|
|US5527537 *||12 May 1993||18 Jun 1996||Dietl; Hans||Pharmaceutical preparation containing cyclosporine(s) for intravenous administration and a process for its production|
|US5529785 *||7 Nov 1994||25 Jun 1996||Dietl; Hans||Pharmaceutical preparation containing cyclosporin(s) for oral administration and process for producing same|
|US5538737 *||30 Nov 1994||23 Jul 1996||Applied Analytical Industries, Inc.||Oral compositions of H2 -antagonists|
|US5548064 *||24 May 1993||20 Ago 1996||Biotech Australia Pty Limited||Vitamin B12 conjugates with EPO, analogues thereof and pharmaceutical compositions|
|US5597562 *||15 Dic 1993||28 Ene 1997||Kirin-Amgen, Inc.||Oral dosage form of biologically active proteins|
|US5610193 *||22 May 1996||11 Mar 1997||Abbott Laboratories||Pharmaceutical composition|
|US5614491 *||30 Nov 1994||25 Mar 1997||Dr. Rentschler Arzneimittel Gmbh & Co.||Liquid preparations containing cyclosporin and process for preparing same|
|US5622714 *||28 Mar 1996||22 Abr 1997||Dietl; Hans||Pharmaceutical preparation containing cyclosporine(s) for intravenous administration and process for its production|
|US5633226 *||20 Abr 1995||27 May 1997||Lds Technologies, Inc.||Convertible microemulsion formulations|
|US5637317 *||8 Mar 1996||10 Jun 1997||Dietl; Hans||Pharmaceutical preparation containing cyclosporin(s) for oral administration and process for producing same|
|US5646109 *||20 Abr 1995||8 Jul 1997||Lds Technologies, Inc.||Convertible microemulsion formulations|
|US5653987 *||16 May 1995||5 Ago 1997||Modi; Pankaj||Liquid formulations for proteinic pharmaceuticals|
|US5688761 *||15 Oct 1993||18 Nov 1997||Lds Technologies, Inc.||Convertible microemulsion formulations|
|US5698515 *||22 Mar 1995||16 Dic 1997||Institut Neftekhimicheskogo Sinteza Imeni A.V.Topchieva Rossiiskoi Akademii Nauk||Insulin-containing polymer composition for oral administration|
|US5707648 *||16 Nov 1994||13 Ene 1998||Lds Technologies, Inc.||Transparent liquid for encapsulated drug delivery|
|US5725878 *||4 May 1995||10 Mar 1998||Abbott Laboratories||Pharmaceutical composition comprising HIV protease inhibiting compounds|
|US5780434 *||18 Mar 1994||14 Jul 1998||Ferring B.V.||Composition for oral administration of peptides|
|US5824638 *||22 May 1995||20 Oct 1998||Shire Laboratories, Inc.||Oral insulin delivery|
|US5827822 *||25 Mar 1996||27 Oct 1998||Sangstat Medical Corporation||Cyclosporin a formulations as nanoparticles|
|US5858401 *||22 Ene 1997||12 Ene 1999||Sidmak Laboratories, Inc.||Pharmaceutical composition for cyclosporines|
|US5869466 *||22 May 1996||9 Feb 1999||Biotech Australia Pty Limited||Vitamin B12 mediated oral delivery systems for GCSF|
|US5876749 *||4 May 1995||2 Mar 1999||Abbott Laboratories||Pharmaceutical composition|
|US5883103 *||7 Jun 1995||16 Mar 1999||Shire Laboratories Inc.||Oral acyclovir delivery|
|US5897876 *||20 Jun 1997||27 Abr 1999||Shire Laboratories Inc.||Emulsified drug delivery system|
|US5912011 *||8 Mar 1995||15 Jun 1999||R. P. Scherer Corporation||Solvent system to be enclosed in capsules|
|US5912014 *||15 Mar 1996||15 Jun 1999||Unigene Laboratories, Inc.||Oral salmon calcitonin pharmaceutical products|
|US5948436 *||13 Mar 1995||7 Sep 1999||Abbott Laboratories||Pharmaceutical composition|
|US5952004 *||17 Mar 1995||14 Sep 1999||Shire Laboratories Inc.||Emulsified drug delivery systems|
|US5985321 *||29 Abr 1997||16 Nov 1999||Novartis Ag||Soft gelatin capsule manufacture|
|US6004580 *||28 Abr 1995||21 Dic 1999||Leiras Oy||Pharmaceutical compositions derived from microemulsion-based gels|
|US6011011 *||20 Mar 1995||4 Ene 2000||Pharmacia & Upjohn Company||Sustained-release protein formulations|
|US6054441 *||5 Jun 1995||25 Abr 2000||Pro-Neuron, Inc.||Oxypurine nucleosides and their congeners, and acyl derivatives thereof, for improvement of hematopoiesis|
|US6057289 *||30 Abr 1999||2 May 2000||Pharmasolutions, Inc.||Pharmaceutical composition comprising cyclosporin in association with a carrier in a self-emulsifying drug delivery system|
|US6060459 *||5 Jun 1995||9 May 2000||Pro-Neuron, Inc.||Enhancing blood cell count with oxypurine nucleosides|
|US6086918 *||14 Mar 1997||11 Jul 2000||Unigene Laboratories, Inc.||Oral peptide pharmaceutical products|
|US6103216 *||16 May 1995||15 Ago 2000||The Board Of Regents Acting For And On Behalf Of The University Of Michigan||Hepatocyte-selective oil-in-water emulsion|
|US6153592 *||9 Nov 1992||28 Nov 2000||Port Systems, Llc||Enhancing the bioavailability of proteolytically labile therapeutic agents|
|US6153632 *||24 Feb 1997||28 Nov 2000||Rieveley; Robert B.||Method and composition for the treatment of diabetes|
|US6187333 *||20 Sep 1999||13 Feb 2001||Diabex, Inc.||Method for treating, controlling, and preventing diabetes mellitus|
|US6191105 *||27 Oct 1997||20 Feb 2001||Protein Delivery, Inc.||Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin|
|US6245349||23 Feb 1996||12 Jun 2001||éLAN CORPORATION PLC||Drug delivery compositions suitable for intravenous injection|
|US6258808||17 Oct 2000||10 Jul 2001||Novartis Ag||Pharmaceutical composition|
|US6262022||19 Ene 2000||17 Jul 2001||Novartis Ag||Pharmaceutical compositions containing cyclosporin as the active agent|
|US6262253 *||5 Feb 1999||17 Jul 2001||Biotech Australia Pty Limited||Vitamin B12 conjugates with gcsf, analogues thereof and pharmaceutical compositions|
|US6267985 *||30 Jun 1999||31 Jul 2001||Lipocine Inc.||Clear oil-containing pharmaceutical compositions|
|US6280770||13 Ago 1999||28 Ago 2001||Cima Labs Inc.||Microemulsions as solid dosage forms for oral administration|
|US6291495||30 Jun 2000||18 Sep 2001||Robert B. Rieveley||Method and composition for the treatment of diabetes|
|US6309663||17 Ago 1999||30 Oct 2001||Lipocine Inc.||Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents|
|US6309665||2 Feb 2001||30 Oct 2001||Gattefosse S.A.||Composition with sustained release of active principle, capable of forming a microemulsion|
|US6312466 *||22 May 1995||6 Nov 2001||Board Of Regents, University Of Texas System||Prosthesis containing a solution of polyethylene glycol|
|US6372206||15 Mar 1996||16 Abr 2002||University Of Florida||Orally-administered interferon-TAU compositions and methods|
|US6420355||5 Abr 2001||16 Jul 2002||Novartis Ag||Pharmaceutical compositions containing cyclosporins|
|US6436430||10 Dic 1999||20 Ago 2002||Pharmasolutions, Inc.||Self-emulsifying compositions for drugs poorly soluble in water|
|US6458383||29 Dic 2000||1 Oct 2002||Lipocine, Inc.||Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin|
|US6475519||28 Ene 1998||5 Nov 2002||Novartis Ag||Oil-free pharmaceutical compositions containing cyclosporin A|
|US6486124||17 Oct 2001||26 Nov 2002||Novartis Ag||Cyclosporin compositions and process therefor|
|US6503883||28 Nov 2000||7 Ene 2003||Novartis Ag||Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis|
|US6541001||21 Ago 2000||1 Abr 2003||Teva Pharmaceutical Industries, Ltd.||Vaccine composition and method of using the same|
|US6555126||2 Ene 2001||29 Abr 2003||Diabex, Inc.||Method for treating, controlling, and preventing Diabetes Mellitus|
|US6555132||17 Oct 2000||29 Abr 2003||Novartis Ag||Soft gelatin capsule manufacture|
|US6582718||27 Ago 2001||24 Jun 2003||Novartis Ag||Cyclosporin compositions|
|US6589536||7 Feb 2000||8 Jul 2003||Novartis Ag||Soft gelatin capsule manufacture|
|US6592869||28 Feb 2001||15 Jul 2003||Teva Pharmaceutical Industries, Ltd.||Vaccine composition and method of using the same|
|US6613353||22 Nov 2000||2 Sep 2003||Pii Drug Delivery, Llc||Pharmaceutical formulations|
|US6638522||10 Dic 1999||28 Oct 2003||Pharmasolutions, Inc.||Microemulsion concentrate composition of cyclosporin|
|US6692771||23 Feb 2001||17 Feb 2004||Cima Labs Inc.||Emulsions as solid dosage forms for oral administration|
|US6713452||4 Jun 2001||30 Mar 2004||Nobex Corporation||Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same|
|US6723339||6 Nov 2001||20 Abr 2004||Novartis Ag||Oil-free pharmaceutical compositions containing cyclosporin A|
|US6759058 *||16 Ago 2001||6 Jul 2004||Western Center For Drug Development College Of Pharmacy Western University Of Health Sciences||Enteric-coated proliposomal formulations for poorly water soluble drugs|
|US6761903||8 Jun 2001||13 Jul 2004||Lipocine, Inc.||Clear oil-containing pharmaceutical compositions containing a therapeutic agent|
|US6828297||4 Jun 2001||7 Dic 2004||Nobex Corporation||Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same|
|US6828305||4 Jun 2001||7 Dic 2004||Nobex Corporation||Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same|
|US6844459||20 May 2003||18 Ene 2005||Novartis Ag||Pharmaceutical Composition|
|US6849269||24 Abr 2002||1 Feb 2005||Western University Of Health Sciences||Proliposomal drug delivery system|
|US6858580||4 Jun 2001||22 Feb 2005||Nobex Corporation||Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same|
|US6867183||5 Sep 2002||15 Mar 2005||Nobex Corporation||Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith|
|US6913903||21 Dic 2001||5 Jul 2005||Nobex Corporation||Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same|
|US6942854||21 Dic 2001||13 Sep 2005||University Of Florida||Orally-administered interferon-tau compositions and methods|
|US6951841||15 Dic 2000||4 Oct 2005||Novartis Ag||Pharmaceutical compositions of macrolides or cyclosporine with a polyethoxylated saturated hydroxy-fatty acid|
|US6956023||19 Abr 2002||18 Oct 2005||University Of Florida||Materials and methods for providing nutrition to neonates|
|US7030084||10 Feb 2004||18 Abr 2006||Nobex Corporation||Drug-oligomer conjugates with polyethylene glycol components|
|US7060675||13 Feb 2002||13 Jun 2006||Nobex Corporation||Methods of treating diabetes mellitus|
|US7070802||5 Mar 2001||4 Jul 2006||Pliva, Inc.||Pharmaceutical compositions for lipophilic drugs|
|US7078054||13 May 2003||18 Jul 2006||Novartis Ag||Soft gelatin capsule manufacture|
|US7084114||29 Abr 2004||1 Ago 2006||Nobex Corporation||Mixtures of insulin drug-oligomer comprising polyalkylene glycol|
|US7084121||23 Mar 2004||1 Ago 2006||Nobex Corporation||Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same|
|US7166571||5 Mar 2003||23 Ene 2007||Biocon Limited||Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same|
|US7169889||19 Jun 2000||30 Ene 2007||Biocon Limited||Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin|
|US7192588||10 Jun 2002||20 Mar 2007||Teva Pharmaceutical Industries, Ltd.||Vaccine composition and method of using the same|
|US7196059||5 Mar 2003||27 Mar 2007||Biocon Limited||Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith|
|US7214367||27 Oct 2003||8 May 2007||University Of Florida||Orally-administered interferon-tau compositions and methods|
|US7226932||29 Abr 2003||5 Jun 2007||G.D. Searle Llc||Self-emulsifying drug delivery system|
|US7307166||5 Jun 1995||11 Dic 2007||Wellstat Therapeutics Corporation||Oxpurine nucleosides and their congeners, and acyl, derivatives thereof, for improvement of hematopoiesis|
|US7312192||14 Mar 2003||25 Dic 2007||Biocon Limited||Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same|
|US7381702||15 Jun 2006||3 Jun 2008||Biocon Limited||Methods of treating diabetes mellitus|
|US7423014||21 Dic 2005||9 Sep 2008||Biocon Limited||Insulin conjugates for treating diabetes mellitus|
|US7470663||4 May 2006||30 Dic 2008||Biocon Limited||Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same|
|US7601688||13 Jun 2003||13 Oct 2009||Biocon Limited||Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus|
|US7605123||20 Oct 2009||Biocon Ltd.||Fatty acid formulations for oral delivery of proteins and peptides, and uses thereof|
|US7611864||30 Sep 2004||3 Nov 2009||Biocon Limited||Proinsulin polypeptide-oligomer conjugates|
|US7651995||15 Abr 2004||26 Ene 2010||Axcess Limited||Absorption enhancers such as e.g. BHT, BHA or propyl gallate|
|US7713932||8 Nov 2002||11 May 2010||Biocon Limited||Calcitonin drug-oligomer conjugates, and uses thereof|
|US7732404||28 Feb 2006||8 Jun 2010||Dexcel Ltd||Pro-nanodispersion for the delivery of cyclosporin|
|US7799340||15 Mar 2007||21 Sep 2010||Watson Laboratories, Inc.||Pharmaceutical compositions for lipophilic drugs|
|US7872095||18 Ene 2011||Biocon Limited||Insulin-oligomer conjugates, formulations and uses thereof|
|US7875700||19 Jul 2005||25 Ene 2011||Biocon Limited||Cation complexes of insulin compound conjugates, formulation and uses thereof|
|US7988995||30 Jul 2002||2 Ago 2011||Watson Laboratories, Inc.||Pharmaceutical compositions for lipophilic drugs|
|US8030269||27 Oct 2009||4 Oct 2011||Biocon Limited||Calcitonin drug-oligomer conjugates, and uses thereof|
|US8088734||20 Ene 2004||3 Ene 2012||Unigene Laboratories Inc.||Oral delivery of peptides|
|US8114833||17 May 2006||14 Feb 2012||Novo Nordisk A/S||Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices|
|US8114959||1 Ago 2008||14 Feb 2012||Novo Nordisk A/S||Stabilized pharmaceutical peptide compositions|
|US8119157||7 Abr 2006||21 Feb 2012||Watson Laboratories, Inc.||Pharmaceutical compositions for lipophilic drugs|
|US8173168 *||28 Sep 2006||8 May 2012||Novartis Pharma Ag||Dispersible macromolecule compositions and methods for their preparation and use|
|US8201554||13 Mar 2009||19 Jun 2012||Injet Digital Aerosols Limited||Inhalation device having an optimized air flow path|
|US8241670||14 Abr 2005||14 Ago 2012||Chiasma Inc.||Compositions capable of facilitating penetration across a biological barrier|
|US8314058 *||15 Abr 2004||20 Nov 2012||Axcess Limited||Uptake of macromolecules|
|US8329198||25 Oct 2011||11 Dic 2012||Chiasma Inc.||Pharmaceutical compositions and related methods of delivery|
|US8337895||29 Jul 2009||25 Dic 2012||Novartis Ag||Spray drying process control of drying kinetics|
|US8338374||13 Dic 2004||25 Dic 2012||Pharmacia Corporation||Stable growth hormone liquid formulation|
|US8486389||15 Jun 2004||16 Jul 2013||Oxthera, Inc.||Compositions and methods for treating or preventing oxalate-related disease|
|US8535695||15 Sep 2011||17 Sep 2013||Chiasma Inc.||Pharmaceutical compositions and related methods of delivery|
|US8545836 *||14 Dic 2006||1 Oct 2013||Oxthera, Inc.||Pharmaceutical compositions and methods for treating oxalate-dependent conditions|
|US8563685||20 Oct 2009||22 Oct 2013||Biocon Limited||Fatty acid formulations and oral delivery of proteins and peptides, and uses thereof|
|US8614181||5 Nov 2009||24 Dic 2013||Novo Nordisk A/S||Stabilized pharmaceutical peptide compositions|
|US8658202||30 Nov 2004||25 Feb 2014||Western University Of Health Sciences||Coated drug delivery formulations|
|US8668937||17 Mar 2012||11 Mar 2014||Transdermal Biotechnology, Inc.||Topical nitric oxide systems and methods of use thereof|
|US8710181||26 Ago 2005||29 Abr 2014||Novo Nordisk A/S||Use of tris(hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins|
|US8748376||21 Dic 2009||10 Jun 2014||Novo Nordisk A/S||Stable formulations of peptides|
|US8778922||22 Ago 2012||15 Jul 2014||Lipocine Inc.||Steroidal compositions|
|US8846618||24 May 2010||30 Sep 2014||Novo Nordisk A/S||Stable formulation of modified GLP-1|
|US8865695||26 Feb 2014||21 Oct 2014||Lipocine Inc.||Steroidal compositions|
|US8871254||13 Mar 2013||28 Oct 2014||Transdermal Biotechnology, Inc.||Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system|
|US8871255||13 Mar 2013||28 Oct 2014||Transdermal Biotechnology, Inc.||Treatment of skin and soft tissue infection with nitric oxide|
|US8871256||13 Mar 2013||28 Oct 2014||Transdermal Biotechnology, Inc.||Methods and systems for treatment of inflammatory diseases with nitric oxide|
|US8871257||13 Mar 2013||28 Oct 2014||Transdermal Biotechnology, Inc.||Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery|
|US8871258||13 Mar 2013||28 Oct 2014||Transdermal Biotechnology, Inc.||Treatment and prevention of learning and memory disorders|
|US8871259||13 Mar 2013||28 Oct 2014||Transdermal Biotechnology, Inc.||Techniques and systems for treatment of neuropathic pain and other indications|
|US8871260||13 Mar 2013||28 Oct 2014||Transdermal Biotechnology, Inc.||Methods and compositions for muscular and neuromuscular diseases|
|US8871261||13 Mar 2013||28 Oct 2014||Transdermal Biotechnology, Inc.||Cancer treatments and compositions for use thereof|
|US8871262||13 Mar 2013||28 Oct 2014||Transdermal Biotechnology, Inc.||Compositions and methods for treatment of osteoporosis and other indications|
|US8889180 *||7 Oct 2011||18 Nov 2014||Western University Of Health Sciences||Coated drug delivery formulations|
|US8900575||15 Dic 2006||2 Dic 2014||Oxthera Intellectual Property Ab||Compositions and methods for oxalate reduction|
|US9034858||31 May 2012||19 May 2015||Lipocine Inc.||High-strength testosterone undecanoate compositions|
|US9050248||22 Jul 2013||9 Jun 2015||Transdermal Biotechnology, Inc.||Methods of delivering stable topical drug compositions|
|US9060925||22 Jul 2013||23 Jun 2015||Transdermal Biotechnology, Inc.||Methods of delivering stable topical drug compositions|
|US9101596||24 Ene 2011||11 Ago 2015||Biocon Limited||Cation complexes of insulin compound conjugates, formulations and uses thereof|
|US9102758||18 Ene 2011||11 Ago 2015||Biocon Limited||Insulin-oligomer conjugates, formulations and uses thereof|
|US20040086534 *||27 Oct 2003||6 May 2004||University Of Florida||Orally-administered interferon-tau compositions and methods|
|US20040161458 *||18 Feb 2004||19 Ago 2004||Armin Meinzer||Oil-free pharmaceutical compositions containing cyclosporin A|
|US20040195549 *||4 Abr 2003||7 Oct 2004||Clifford Adams||Lipid-soluble formulations containing mixtures of antioxidants|
|US20040197323 *||20 Ene 2004||7 Oct 2004||Unigene Laboratories, Inc.||Oral delivery of peptides|
|US20040198949 *||29 Abr 2004||7 Oct 2004||Ekwuribe Nnochiri N.||Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same|
|US20040223948 *||10 Feb 2004||11 Nov 2004||Ekwuribe Nnochiri N.||Drug-oligomer conjugates with polyethylene glycol components|
|US20040234514 *||15 Jun 2004||25 Nov 2004||Harmeet Sidhu||Compositions and methods for treating or preventing oxalate-related disease|
|US20050003976 *||28 Jul 2004||6 Ene 2005||Shiseido Company, Ltd.||Sympathetic nerve-stimulating fragrant compositions|
|US20050031687 *||1 Jul 2004||10 Feb 2005||Betageri Guru V.||Enteric-coated proliposomal formulations for poorly water soluble drugs|
|US20050048087 *||8 Oct 2004||3 Mar 2005||Ulrich Posanski||Pharmaceutical compositions for sparingly soluble therapeutic agents|
|US20050080001 *||30 Sep 2004||14 Abr 2005||Richard Soltero||Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same|
|US20050107297 *||12 May 2004||19 May 2005||Holmes Christopher P.||Novel poly(ethylene glycol) modified compounds and uses thereof|
|US20050136121 *||16 Dic 2004||23 Jun 2005||Shear/Kershman Laboratories, Inc.||Oral peptide delivery system with improved bioavailability|
|US20050152965 *||30 Nov 2004||14 Jul 2005||Betageri Guru V.||Coated drug delivery formulations|
|US20050171193 *||6 Ene 2005||4 Ago 2005||Lipocine, Inc.||Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs|
|US20050191403 *||22 Nov 2004||1 Sep 2005||Glutagen Pty Ltd||Palliative treatment for gluten intolerance|
|US20060003002 *||4 May 2005||5 Ene 2006||Lipocine, Inc.||Pharmaceutical compositions with synchronized solubilizer release|
|US20060019873 *||19 Jul 2005||26 Ene 2006||Balasingam Radhakrishnan||Cation complexes of insulin compound conjugates, formulations and uses thereof|
|US20060019874 *||19 Jul 2005||26 Ene 2006||Nobex Corporation||Cation complexes of insulin compund conjugates, formulation and uses thereof|
|US20100086587 *||17 Dic 2007||8 Abr 2010||Victor Morrison Young||Hard shell capsule formulations|
|US20110293714 *||18 Sep 2009||1 Dic 2011||Novo Nordisk A/S||Pharmaceutical compositions suitable for oral administration of derivatized insulin peptides|
|US20120027864 *||2 Feb 2012||Western University Of Health Sciences||Coated drug delivery formulations|
|US20120213855 *||23 Ago 2012||Cima Labs Inc.||Dosage forms for weakly ionizable compounds|
|CN100406004C||21 Ago 2000||30 Jul 2008||特瓦制药工业有限公司||Vaccine composition and method of using same|
|CN101772352B||28 Abr 2008||23 May 2012||理研维他命株式会社||Liquid composition for soft-capsule filling|
|DE19540669A1 *||31 Oct 1995||9 May 1996||Hoffmann La Roche||Non-parenteral interferon compsn.|
|EP0529927A1 *||19 Ago 1992||3 Mar 1993||MITSUI TOATSU CHEMICALS, Inc.||A process for preparing a toner resin|
|EP0589843A1 *||21 Sep 1993||30 Mar 1994||Sandoz Ag||Pharmaceutical compositions containing cyclosporins|
|EP1110545A2 *||10 Ago 1994||27 Jun 2001||Novartis AG||Pharmaceutical preparations for the targeted treatment of Morbus Crohn and Colitis Ulcerosa|
|EP1142568A1 *||21 Sep 1993||10 Oct 2001||Novartis AG||Pharmaceutical compositions containing cyclosporins|
|EP1565163A2 †||25 Nov 2003||24 Ago 2005||Lipoid GmbH||Emulsive water-soluble concentrates|
|EP1933862A2 *||31 Ago 2006||25 Jun 2008||Oramed Pharmaceuticals Inc.||Methods and compositions for oral administration of proteins|
|EP2125191A2 *||17 Dic 2007||2 Dic 2009||MW Encap Limited||Hard shell capsule formulations|
|EP2394656A2 *||18 Nov 2004||14 Dic 2011||Novo Nordisk A/S||Propylene Glycol-containing peptide formulations which are optimal for production and for use in injection devices|
|EP2722054A1 *||31 Ago 2006||23 Abr 2014||Oramed Pharmaceuticals Inc.||Methods and compositions for oral administration of proteins|
|WO1994021286A1 *||18 Mar 1994||29 Sep 1994||Fjellestad Paulsen Anne||Composition for oral administration of peptides|
|WO1994027613A1 *||24 May 1994||8 Dic 1994||Biotech Australia Pty Ltd||Vitamin b12 mediated oral delivery systems for gcsf and epo|
|WO1994027641A1 *||24 May 1994||8 Dic 1994||Biotech Australia Pty Ltd||Amplification of the vitamin b12 uptake system using polymers|
|WO1995005078A1 *||5 Ago 1994||23 Feb 1995||Pharmos Corp||Submicron emulsions for delivery of peptides|
|WO1995006463A1 *||15 Ago 1994||9 Mar 1995||William J Curatolo||Pharmaceutical compositions containing anionic surfactants|
|WO1995006464A1 *||10 Ago 1994||9 Mar 1995||Galenik Labor Freiburg Gmbh||Pharmaceutical preparations for the targeted treatment of morbus crohn and colitis ulcerosa|
|WO1995007696A1 *||30 Ago 1994||23 Mar 1995||Abbott Lab||Pharmaceutical composition of hiv-protease inhibitors|
|WO1996016640A1 *||22 Nov 1995||6 Jun 1996||Applied Analytical Ind Inc||Oral compositions of h2-antagonists|
|WO1996037215A1 *||7 May 1996||28 Nov 1996||Pharmavene Inc||Oral insulin delivery|
|WO1997033531A1 *||14 Mar 1997||18 Sep 1997||Unigene Lab Inc||Oral peptide pharmaceutical products|
|WO1997035603A1 *||21 Mar 1997||2 Oct 1997||Sangstat Medical Corp||Cyclosporin a formulations as nanoparticles|
|WO2000007573A1 *||30 Jul 1999||17 Feb 2000||Barthelemy Philippe||Composition with prolonged release of active principle capable of forming a micro-emulsion|
|WO2000009093A1 *||13 Ago 1999||24 Feb 2000||Cima Labs Inc||Microemulsions as solid dosage forms for oral administration|
|WO2001013896A1||21 Ago 2000||1 Mar 2001||Teva Pharma||A vaccine composition and method of using the same|
|WO2002085304A2 *||24 Abr 2002||31 Oct 2002||Western Ct For Drug Dev Colleg||Proliposomal drug delivery system|
|WO2005049061A2 *||18 Nov 2004||2 Jun 2005||Novo Nordisk As||Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices|
|WO2005063298A1||13 Dic 2004||14 Jul 2005||Pharmacia Corp||Stable growth hormone liquid formulation|
|WO2006097793A2 *||14 Abr 2005||21 Sep 2006||Chiasma Ltd||Compositions capable of facilitating penetration across a biological barrier|
|WO2006103657A2 *||27 Mar 2006||5 Oct 2006||Dexcel Pharma Technologies Ltd||A solid composition for intra-oral delivery of insulin|
|WO2009041105A1 *||28 Abr 2008||2 Abr 2009||Masao Iizuka||Liquid composition for soft-capsule filling|
|WO2011086093A2||12 Ene 2011||21 Jul 2011||Novo Nordisk A/S||Pharmaceutical compositions for oral administration of insulin peptides|
|Clasificación de EE.UU.||424/85.2, 424/474, 424/490, 424/455, 424/463, 514/20.5, 514/5.9, 514/11.3, 514/10.9, 514/13.7, 514/20.1, 514/11.9, 514/7.7|
|Clasificación internacional||A61K38/27, A61K38/28, A61K38/23, A61K38/18, A61K9/48, A61K9/107|
|Clasificación cooperativa||A61K9/1075, A61K9/4891, A61K9/4858, A61K38/28, A61K9/4866, A61K38/27, A61K38/1816, A61K38/23|
|Clasificación europea||A61K38/18B, A61K9/48H6, A61K38/23, A61K9/48Z, A61K38/27, A61K9/107D, A61K9/48H4, A61K38/28|
|25 Nov 1991||AS||Assignment|
Owner name: APPLIED ANALYTICAL INDUSTRIES, INC.,, NORTH CAROLI
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:DESAI, ASHOK J.;REEL/FRAME:005929/0063
Effective date: 19911122
|24 Oct 1996||FPAY||Fee payment|
Year of fee payment: 4
|25 Oct 1999||AS||Assignment|
|21 Nov 2000||REMI||Maintenance fee reminder mailed|
|26 Dic 2000||SULP||Surcharge for late payment|
Year of fee payment: 7
|26 Dic 2000||FPAY||Fee payment|
Year of fee payment: 8
|7 Sep 2001||AS||Assignment|
|8 Ene 2002||AS||Assignment|
|2 May 2002||AS||Assignment|
|30 Abr 2004||AS||Assignment|
Owner name: SILVER POINT FINANCE LLC, CONNECTICUT
Free format text: SECURITY AGREEMENT;ASSIGNORS:AAIPHARMA INC.;AAIPHARMA LLC( A DELAWARE LIMITED LIABILITY COMPANY);REEL/FRAME:014580/0798;SIGNING DATES FROM 20040423 TO 20040424
|12 May 2004||AS||Assignment|
|22 Sep 2004||FPAY||Fee payment|
Year of fee payment: 12
|7 Mar 2006||AS||Assignment|
Owner name: AAIPHARMA INC., NORTH CAROLINA
Free format text: RELEASE BY SECURED PARTY;ASSIGNORS:SILVER POINT FINANCE LLC;WACHOVIA BANK, NATIONAL ASSOCIATION;REEL/FRAME:017262/0312;SIGNING DATES FROM 20060228 TO 20060302
Owner name: AAIPHARMA LLC, NORTH CAROLINA
Free format text: RELEASE BY SECURED PARTY;ASSIGNORS:SILVER POINT FINANCE LLC;WACHOVIA BANK, NATIONAL ASSOCIATION;REEL/FRAME:017262/0312;SIGNING DATES FROM 20060228 TO 20060302
|17 Jul 2009||AS||Assignment|
Owner name: AAIPHARMA SERVICES CORP.,NORTH CAROLINA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:AAIPHARMA INC.;REEL/FRAME:022973/0095
Effective date: 20090715
|21 Jul 2009||AS||Assignment|
Owner name: WATER STREET HEALTHCARE PARTNERS II L.P.,ILLINOIS
Free format text: SECURITY AGREEMENT;ASSIGNORS:AAIPHARMA SERVICES CORP.;AAI HOLDINGS CORP.;REEL/FRAME:022980/0410
Effective date: 20090715
|13 Ene 2011||AS||Assignment|
Owner name: AAIPHARMA SERVICES CORP., NORTH CAROLINA
Free format text: RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY (PATENTS) RECORDED AT REEL/FRAME 022980/0410;ASSIGNOR:WATER STREET HEALTHCARE PARTNERS II L.P.;REEL/FRAME:025624/0812
Effective date: 20110113
Owner name: REGIONS BANK, TENNESSEE
Free format text: SECURITY AGREEMENT;ASSIGNOR:AAIPHARMA SERVICES CORP.;REEL/FRAME:025627/0677
Effective date: 20110113
Owner name: AAI HOLDINGS CORP., NORTH CAROLINA
Free format text: RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY (PATENTS) RECORDED AT REEL/FRAME 022980/0410;ASSIGNOR:WATER STREET HEALTHCARE PARTNERS II L.P.;REEL/FRAME:025624/0812
Effective date: 20110113